|
FDA monitored phase II Clinical trials of Presview scleral implants and the Scleral Spacing Procedure (SSP) for the surgical reversal of presbyopia are underway at the New York Eye and Ear Infirmary's Vision Correction Center. We are currently recruiting additional patients for these studies. If you think that you fit the criteria below and are interested in participating in one of these studies, please contact us at the number below:
Inclusion Criteria
1) Patients between 50 to 60 years old
2) Best corrected distance vision 20/20
3) Uncorrected near vision less than 20/63
4) Distance SE refraction between -0.50 and +0.75
5) Less than 1.0 diopters of astigmatism
6) Patient still has their natural lens
7) Able to comply with the requirements and restrictions of the
study
Exclusion Criteria
1) Chronic imflammation in the eye
2) Scleral thickness less than 530 microns
3) Any prior eye surgery (including LASIK or other vision correction)
4) Chronic ocular disease
5) Acute ocular disease
6) Chronic systemic disease
We are using Refocus (formerly PresbyCorp) Group's Presview implant during these trials, the same implant that Dr. Soloway has successfully used on numerous patients treated abroad.
These trials are sponsored by Refocus Group. Patients selected for this trial will have all medical, surgical and hospital care fees paid for by the sponsor.
If you are interested in this surgery and think you might be eligible for the protocol, please call Vista Alliance Eye Care Associates at 212 758 3838 and ask to speak to one of our Vision Coordinators about SSP surgery.
Or click on these links for more information:
|
